Norinchukin Bank The boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 88,926 shares of the medical research company’s stock after acquiring an additional 3,349 shares during the quarter. Norinchukin Bank The’s holdings in Amgen were worth $15,316,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in AMGN. RNC Capital Management LLC raised its position in Amgen by 10.0% in the first quarter. RNC Capital Management LLC now owns 129,993 shares of the medical research company’s stock worth $21,328,000 after acquiring an additional 11,822 shares in the last quarter. Meadow Creek Investment Management LLC raised its position in Amgen by 22.4% in the first quarter. Meadow Creek Investment Management LLC now owns 25,200 shares of the medical research company’s stock worth $4,135,000 after acquiring an additional 4,608 shares in the last quarter. Affinity Investment Advisors LLC raised its position in Amgen by 1.0% in the first quarter. Affinity Investment Advisors LLC now owns 86,970 shares of the medical research company’s stock worth $14,269,000 after acquiring an additional 884 shares in the last quarter. Main Street Research LLC raised its position in Amgen by 1.0% in the first quarter. Main Street Research LLC now owns 68,468 shares of the medical research company’s stock worth $11,233,000 after acquiring an additional 692 shares in the last quarter. Finally, Morningstar Investment Services LLC raised its position in Amgen by 283.8% in the first quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after acquiring an additional 367,894 shares in the last quarter. Hedge funds and other institutional investors own 78.38% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at $178.69 on Tuesday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. The company has a market capitalization of $129,710.00, a price-to-earnings ratio of 14.09, a P/E/G ratio of 2.57 and a beta of 1.36. Amgen Inc. has a 52 week low of $138.83 and a 52 week high of $191.10.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business’s revenue for the quarter was down .7% compared to the same quarter last year. During the same quarter last year, the company earned $3.02 earnings per share. research analysts expect that Amgen Inc. will post 12.66 EPS for the current year.
Amgen announced that its Board of Directors has initiated a share repurchase program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be paid a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s payout ratio is currently 41.55%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $171.58, for a total value of $261,659.50. Following the sale, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at approximately $9,888,326.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,050 shares of company stock worth $1,239,673. Corporate insiders own 0.19% of the company’s stock.
A number of research analysts have recently weighed in on AMGN shares. Oppenheimer restated a “buy” rating and issued a $203.00 price target on shares of Amgen in a research report on Friday, October 6th. Mizuho restated a “buy” rating and issued a $198.00 price target on shares of Amgen in a research report on Friday, October 6th. Cann restated a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Bank of America raised their price target on Amgen to $210.00 and gave the company a “buy” rating in a research report on Thursday, October 5th. Finally, Jefferies Group restated a “buy” rating and issued a $200.00 price target on shares of Amgen in a research report on Monday, September 25th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $190.22.
COPYRIGHT VIOLATION WARNING: “Amgen Inc. (AMGN) Shares Bought by Norinchukin Bank The” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/05/amgen-inc-amgn-shares-bought-by-norinchukin-bank-the.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.